Skip to main content
Premium Trial:

Request an Annual Quote

Roche Official: Leukemia, p53 Microarrays Next on the Agenda

SAN DIEGO, Feb. 22 (GenomeWeb News) - Following a talk at the Clinical Genomics conference here last week, Walter Koch, senior director of Roche's pharmacogenomics department, provided a few details concerning the company's upcoming leukemia microarray and p53 AmpliChip products, which are being produced using technology the company licensed from Affymetrix.

"We will need a diagnostic for resequencing p53 if [Roche's] MDM2-inhibitors make it through trials," Koch said of the company's AmpliChip p53 mutational analysis test. The cancer drugs are currently "close to Phase I," he said.

Koch also clarified the capabilities of an upcoming leukemia microarray, which will classify tumor cells into one of 20 subtypes, he said.

The leukemia classification microarray is slated for rollout during 2005 and into 2006, while the AmpliChip p53 test has been targeted for research use in 2006.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.